

## SPECTRAL MEDICAL INC. WITHDRAWS PUBLIC OFFERING

### NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, March 12, 2020 -- **Spectral Medical Inc.** ("**Spectral**" or the "**Company**") (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that, in light of current market conditions, it is withdrawing its preliminary short form prospectus previously filed on March 5, 2020.

#### About Spectral

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ("**PMX**"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 170,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada.

Spectral, through its wholly owned subsidiary, Dialco Medical Inc. ("**Dialco**"), is also commercializing a new proprietary platform, "SAMI", targeting the renal replacement therapy ("**RRT**") market. Dialco is also seeking regulatory approval for "DIMI" which is based on the same RRT platform, but will be intended for home hemodialysis use.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit [www.spectraldx.com](http://www.spectraldx.com)

#### Forward-looking statement

*Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities, general economic, market and business conditions, as well as other risks and uncertainties which are more fully described in Spectral's Annual Information Form dated March 28, 2018, and in other filings of Spectral with securities and regulatory authorities which are available at [www.sedar.com](http://www.sedar.com). Spectral does not undertake any obligation to update forward-looking statements should these assumptions change. Nothing in this document should be construed as either an offer to sell or a solicitation to buy or sell Spectral securities.*

*The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.*

For further information please contact:

Dr. Paul Walker  
President and CEO  
Spectral Medical Inc.  
416-626-3233 ext. 2100  
[pwalker@spectraldx.com](mailto:pwalker@spectraldx.com)

Chris Seto  
CFO  
Spectral Medical Inc.  
416-626-3233 ext. 2004  
[cseto@spectraldx.com](mailto:cseto@spectraldx.com)

Ali Mahdavi  
Capital Markets & Investor Relations  
416-962-3300  
[am@spinnakercmi.com](mailto:am@spinnakercmi.com)